Steven Lipkin   Professor of Medicine (Courtesy)

Phone
  • +1 212 746 4014

Publications

Sort by

selected publications

Research

Sort by

Funding awarded

  • PREVENT Cancer Preclinical Drug Development Program: Preclinical Efficacy and Intermediate Endpoint Biomarkers  awarded by National Cancer Institute Principal Investigator 2024 - 2029
  • Toward LNP Vaccine Immune-Interception for Childhood Cancer Predisposition Syndromes  awarded by Alex''s Lemonade Stand Foundation Co-Investigator 2025 - 2029
  • Agr2 regulates host-microbe responses in Crohn''s disease  awarded by National Institute of Diabetes & Digestive & Kidney Diseases Co-Principal Investigator 2025 - 2029
  • CAP-IT Center for LNP RNA Immunoprevention  awarded by National Cancer Institute Co-Principal Investigator 2022 - 2027
  • Multidisciplinary Research Training in Gastroenterology and Hepatology  awarded by National Institute of Diabetes & Digestive & Kidney Diseases Key Personnel 2025 - 2030
  • Immunogenicity of lipid nanoparticles  awarded by National Institute of Allergy & Infectious Diseases Principal Investigator Subaward 2024 - 2028
  • Cancer Immune-Interception for Lynch Syndrome  awarded by MD Anderson Cancer Center Principal Investigator Subaward 2021 - 2026
  • Microbiota, Metabolites, and Colon Neoplasia  awarded by National Cancer Institute Principal Investigator Subaward 2021 - 2026

Background

Contact

full name

  • Steven Lipkin

primary email

  • stl2012@med.cornell.edu

External Relationships

externalRelationships

  • Relationships and collaborations with for-profit and not-for-profit organizations are of vital importance to our faculty because these exchanges of scientific information foster innovation. As experts in their fields, WCM physicians and scientists are sought after by many organizations to consult and educate. WCM and its faculty make this information available to the public, thus creating a transparent environment.

    Ownership refers to any financial stake an individual owns in any company (e.g., stock options, equity interest)Ownership:
    AnaNeo Therapeutics